精神科合作與授權協議（2019-2025）

"精神病學合作與許可協議" 報告以前所未有的方式，全面深入地展現了全球領先的生物製藥公司達成的精神病學交易。

這份經過全面修訂和更新的報告詳細介紹了2019年至2025年間的569項精神科交易。

本報告提供了交易雙方已公佈的付款條款。這些數據有助於深入了解付款條款和其他交易條款。

了解潛在合作夥伴協商條款的彈性，有助於深入了解條款談判過程中可能出現的情況。雖然許多中小企業會尋求詳細的付款條款，但魔鬼藏在細節裡，尤其是在付款方式和權利轉讓方面。

本報告全面列出了自 2019 年以來在 "當前協議" 交易和合作資料庫中記錄的所有合作與許可協議，包括可用的財務條款。報告還包含指向公司及其合作夥伴向美國證券交易委員會提交的實際許可協議文件的線上副本的連結。

本報告的第一章探討了精神病學領域的交易和商業活動。第一章對報告進行了介紹，第二章分析了精神病學領域的交易趨勢。

第三章涵蓋了精神科領域已達成交易的財務條款，以及開發階段的公告。交易按總價值、首付款、里程碑付款和特許權使用費率進行分類。

第四章回顧了在精神科交易中最活躍的 25 家生物製藥公司。 對於已向美國證券交易委員會 (SEC) 披露協議的交易，可透過 "當前協議交易與聯盟" 資料庫在線存取這些協議。

第五章對自 2016 年以來簽署和宣布的、且有協議文件可供查閱的精神病學交易進行了全面深入的回顧。每個交易標題均透過網路連結指向實際的線上協議文件，方便讀者根據需要輕鬆存取每個協議文件。

第六章依治療標靶提供了精神科交易的綜合目錄。

本書還包含大量圖表，展示了自 2019 年以來精神病學交易的趨勢和活動。

此外，本書還提供了一個以公司名稱（A-Z）和技術類型組織的綜合交易目錄。每個交易標題均透過網路連結指向線上交易記錄，並在可用的情況下包含協議文件，方便讀者隨時存取每個協議文件。

主要優勢

精神醫學合作研究和授權協議為讀者提供以下主要優勢：

• 了解 2019 年及以後的交易趨勢
• 瀏覽精神醫學合作與許可交易
• 基準分析 - 確定交易市場價值
• 財務條款 - 預付款、里程碑付款、特許權使用費
• 按公司 A-Z、治療領域和技術類型找到交易目錄
• 主要交易價值
• 最活躍的交易撮合者
• 確定每筆交易的資產和交易條款
• 存取合約文件 - 深入了解交易結構
• 盡職調查 - 評估擬議交易條款與合作夥伴的契合度
• 節省數百小時的研究時間

範圍

• 精神病學合作和授權交易旨在幫助全球領先的生物製藥公司深入了解精神病學領域的趨勢和交易結構。

精神科合作與許可交易包括：

• 生物製藥產業精神醫學交易趨勢
• 合作與授權交易結構概述
• 涵蓋製藥和生物技術的精神病學交易記錄目錄
• 主要精神科交易
• 最活躍的精神科許可公司

精神科合作與許可交易清單如下：

• 公司 A-Z
• 交易金額
• 治療領域
• 技術類型
• 每個交易標題均透過網路連結指向實際的線上交易記錄，方便查閱合約文件（如有）。
• 精神病學合作與許可交易
提供對交易記錄的全面存取權限，包括合約文件。

合約文件分析有助於進行盡職調查，包括：

• 具體授予或選擇哪些權利？
• 合約實際賦予合作夥伴哪些權益？
• 授予了哪些排他性權利？
• 合約的付款結構是什麼？
• 如何進行銷售和付款審計？
• 合約期限是多久？
• 如何定義合約的關鍵條款？
• 智慧財產權的處理和所有權是什麼？
• 誰負責商業化？
• 誰負責開發、供應和生產？
• 如何管理保密性和資訊揭露？
• 如何解決爭議？
• 在什麼情況下可以終止合約？
• 如果所有權發生變更，會發生什麼事？
• 已達成哪些轉許可或分包條款？
• 公司堅持哪些標準條款？
• 哪些標準條款似乎因合作夥伴或交易類型而異？
• 公司主張適用哪種契約法管轄權？

目錄

摘要整理

第一章：引言

第二章：精神醫學交易趨勢

• 引言
• 歷年精神醫學合作狀況
• 按交易類型劃分的精神科合作
• 按行業劃分的精神科合作
• 依研發階段劃分的精神醫學合作
• 按技術類型劃分的精神科合作
• 按治療適應症劃分的精神科合作

第三章 精神醫學聯盟的財務條款

• 引言
• 揭露精神醫學聯盟的財務條款
• 精神醫學聯盟的關鍵價值
• 預付款精神科交易
• 精神科交易中的里程碑付款
• 精神科的特許權使用費率

第四章：精神科護理領域的關鍵交易與經銷商

• 引言
• 精神科聯盟中最活躍的機構
• 精神科護理領域最活躍的談判者名單
• 精神科護理領域價值最高的交易

第五章：精神科合約文件目錄

• 引言
• 精神科聯盟協議及可用合約

第六章：依治療目標劃分的精神科交易

• 引言
• 依治療目標劃分的精神科交易
• 交易目錄
• 交易目錄 -精神病交易（按公司、亞利桑那州、2019-2025 年）
• 交易目錄 - 精神科交易（依技術類型、2019-2025 年）
• 交易類型定義
• 關於研究公司
• 當前合作夥伴
• 當前協議
• 按目前合作夥伴劃分的當前報告標題

Psychiatry Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the psychiatry deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of 569 psychiatry deals from 2019 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of psychiatry dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in psychiatry dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the psychiatry field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in psychiatry dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of psychiatry deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of psychiatry deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in psychiatry deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Psychiatry Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse psychiatry collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Psychiatry Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of psychiatry trends and structure of deals entered into by leading biopharma companies worldwide.

Psychiatry Collaboration and Licensing Deals includes:

• Trends in psychiatry dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of psychiatry deal records covering pharmaceutical and biotechnology
• The leading psychiatry deals by value
• Most active psychiatry licensing dealmakers

In Psychiatry Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Psychiatry Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in psychiatry dealmaking

• 2.1. Introduction
• 2.2. Psychiatry partnering over the years
• 2.3. Psychiatry partnering by deal type
• 2.4. Psychiatry partnering by industry sector
• 2.5. Psychiatry partnering by stage of development
• 2.6. Psychiatry partnering by technology type
• 2.7. Psychiatry partnering by therapeutic indication

Chapter 3 - Financial deal terms for psychiatry partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for psychiatry partnering
• 3.3. Psychiatry partnering headline values
• 3.4. Psychiatry deal upfront payments
• 3.5. Psychiatry deal milestone payments
• 3.6. Psychiatry royalty rates

Chapter 4 - Leading psychiatry deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in psychiatry partnering
• 4.3. List of most active dealmakers in psychiatry
• 4.4. Top psychiatry deals by value

Chapter 5 - Psychiatry contract document directory

• 5.1. Introduction
• 5.2. Psychiatry partnering deals where contract document available

Chapter 6 - Psychiatry dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by psychiatry therapeutic target
• Deal directory
• Deal directory - Psychiatry deals by company A-Z 2019 to 2025
• Deal directory - Psychiatry deals by technology type 2019 to 2025
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Psychiatry partnering since 2019
• Figure 2: Psychiatry partnering by deal type since 2019
• Figure 3: Psychiatry partnering by industry sector since 2019
• Figure 4: Psychiatry partnering by stage of development since 2019
• Figure 5: Psychiatry partnering by technology type since 2019
• Figure 6: Psychiatry partnering by indication since 2019
• Figure 7: Psychiatry deals with a headline value
• Figure 8: Psychiatry deals with upfront payment values
• Figure 9: Psychiatry deals with milestone payment
• Figure 10: Psychiatry deals with royalty rates
• Figure 11: Active psychiatry dealmaking activity since 2019
• Figure 12: Top psychiatry deals by value since 2019